5/24/2021 8:34:40 AM
BioMarin: EMA Grants Request For Accelerated Assessment Of Valoctocogene Roxaparvovec For Severe Hemophilia A
5/19/2021 8:35:21 AM
BioMarin Updates On Results From Open-label Phase 1/2 Study Of Valoctocogene Roxaparvovec
4/30/2021 5:38:22 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) FY22 Rev. Estimate To 2181 M From 2189 M
4/30/2021 5:38:07 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q4 22 Rev. Estimate To 593.6 M From 594.7 M
4/30/2021 5:37:52 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q3 22 Rev. Estimate To 559.1 M From 561.1 M
4/30/2021 5:37:38 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q2 22 Rev. Estimate To 527.0 M From 528.5 M
4/30/2021 5:37:23 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q1 22 Rev. Estimate To 502.0 M From 505.5 M
4/30/2021 5:37:06 PM
Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) FY21 Rev. Estimate To 1795 M From 1750 M
4/30/2021 5:36:54 PM
Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) Q4 21 Rev. Estimate To 441.6 M From 430.4 M
4/30/2021 5:36:38 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q3 21 Rev. Estimate To 434.1 M From 437.0 M
4/30/2021 5:36:23 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q2 21 Rev. Estimate To 434.0 M From 444.6 M
4/30/2021 5:35:55 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) FY22 Estimate To 0.98 From 1.35
4/30/2021 5:35:40 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q4 22 Estimate To 0.47 From 0.62
4/30/2021 5:35:29 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q3 22 Estimate To 0.32 From 0.47
4/30/2021 5:35:18 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q2 22 Estimate To 0.13 From 0.16
4/30/2021 5:35:07 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q1 22 Estimate To 0.07 From 0.10